What Genesis Therapeutics does

Genesis Therapeutics, operating as Genesis Molecular AI, develops an AI-driven platform for small molecule drug discovery that combines proprietary foundation models with physics-based methods. The company targets challenging biological targets where traditional discovery methods have historically high failure rates, and serves major pharmaceutical companies alongside its own internal drug programs.

The core product stack centers on GEMS (Genesis Exploration and Modeling System), an AI operating system for molecular design that runs end-to-end researcher workflows, and Pearl, a next-generation foundation model purpose-built for molecular-scale AI rather than adapted from general-purpose code or image models. The roadmap also includes advanced capabilities such as Model Distillation for efficient deployment and a Zero-shot Pearl System that, per company reporting, surpassed all cofolding models on the OpenBind benchmark. Each cycle on each drug program is intended to generate new molecular data that feeds back into model improvement, creating an internal data flywheel.

Genesis operates a B2B platform model. Revenue mechanics are not publicly disclosed, but the company markets directly to pharmaceutical enterprises, with Incyte as the publicly named strategic partner following an expanded collaboration announced in June 2026. The company appears to be a privately held, venture-backed entity based on the absence of tickers, exchange listings, or investor-relations material in the available sources; ownership structure, funding history, headcount, and financial details are not disclosed in the input data.

Name

Genesis Therapeutics

Website

https://genesistherapeutics.ai

Company type

Private

Founded year

2019

Operating status

Operating

Short description

Genesis Therapeutics (dba Genesis Molecular AI) develops AI foundation models combined with physics-based methods for small molecule drug discovery, serving pharmaceutical partners through its GEMS platform and proprietary Pearl foundation model.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• AI drug discovery
• Small molecule therapeutics
• Molecular foundation models
• Computational chemistry
• Pharmaceutical AI platform

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels2 records

Core offering

Genesis Therapeutics operates an AI drug discovery platform that combines proprietary foundation models with physics-based methods to design small molecule therapeutics for challenging biological targets. Its core offerings include the GEMS AI operating system for molecular design workflows and the Pearl foundation model, used both for the company's own drug programs and for major pharmaceutical partners such as Incyte.

Product overview

Genesis Molecular AI is a unified platform for small molecule drug discovery that combines AI foundation models with physics-based methods. The portfolio includes GEMS (Genesis Exploration and Modeling System), the AI operating system for molecular design that powers the entire workflow, and Pearl Foundation Model, a next-generation foundation model for molecular-scale AI. The platform unifies foundation models with physics to enable researchers to run complete design workflows, generating new data that feeds back into improved AI model capabilities. It serves both Genesis's internal drug programs and major pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• GEMS: The AI operating system for molecular design - an AI platform powered by industry-leading models for drug discovery research workflows.
• Pearl
• Genesis Model Distillation
• Pearl System

Products and services

• GEMS (Genesis Exploration and Modeling System) The AI operating system for molecular design that powers Genesis's full drug discovery workflow; researchers run their complete design workflow on this platform, powered by the company's most advanced AI models.
• Pearl Foundation Model Next-generation foundation model purpose-built for molecular-scale drug discovery; powers molecular design and is the underlying model for the Pearl System on the OpenBind benchmark.
• Genesis Molecular AI Platform Unified platform that combines AI foundation models with physics-based methods for small molecule drug discovery, available to major pharmaceutical partners and used internally for Genesis's own drug programs.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• IncytecoreStrategic or Co-development Partner · 10 June 2026Incyte partnership expansion announced June 10, 2026. Genesis provides AI-powered molecular design capabilities that complement Incyte's drug development expertise. The partnership expansion builds on an existing collaboration to advance small molecule drug discovery programs using Genesis's AI platform.

Recent moves4 records

Expansion highlights4 records

Direct peers

• Atomwise: AI-driven small molecule drug discovery company using structure-based and virtual screening approaches with multiple pharma partnerships. Directly comparable platform-and-partnership model focused on small molecules.
• Isomorphic Labs: Alphabet/DeepMind spinoff applying AlphaFold-era AI foundation models to drug discovery and partnering with major pharma. Directly comparable in foundation-model-first approach and pharma partnership GTM.
• Insilico Medicine: AI-native drug discovery company combining generative AI, biology, and chemistry to discover and develop small molecule drugs for challenging targets. Closely comparable to Genesis in target focus, platform model, and pharma partnership approach.
• Schrödinger, Inc. Public computational chemistry and molecular simulation platform serving pharma partners and running internal programs. Comparable to Genesis in combining physics-based methods with AI for small molecule discovery and operating a hybrid platform-plus-pipeline model.
• Recursion Pharmaceuticals: Techbio company combining high-throughput biology with AI/ML for drug discovery across multiple therapeutic areas. Comparable in AI-driven discovery platform, internal pipeline plus partnerships, and scaling model throughput.
• XtalPi: AI + robotics drug discovery company combining physics-based modeling, AI, and automated synthesis for small molecule R&D. Comparable platform approach and pharma partnership commercialization model.
• Iambic Therapeutics: AI-native drug discovery company developing foundation models for chemistry and biology to design small molecule therapeutics. Closely comparable in foundation model approach to molecular design and pharma collaboration strategy.

Others

• Arctoris: Contract research organization combining automated lab robotics with AI for drug discovery experimentation. Adjacent enabling peer providing experimental data infrastructure that AI-native discovery platforms rely on for the wet-lab validation loop.

Emerging players

• Cradle Bio: Generative AI platform for biology and protein engineering, applying foundation models to design novel biologics. Comparable in foundation-model-first philosophy but focused on proteins rather than small molecules.
• BigHat Biosciences: AI/ML-driven antibody engineering platform with a closed-loop design-build-test-learn workflow. Comparable in wet-lab-integrated AI platform approach but focused on biologics rather than small molecules.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genesis-molecular-ai

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Therapeutics